Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals Begins Phase 3 Trial of Asimadoline in Irritable Bowel Syndrome
06.03.2010Tioga Pharmaceuticals, Inc. announced today that the company has dosed its first subject in a Phase 3 clinical trial to evaluate asimadoline for the treatment of patients with diarrhea-predominant irritable bowel syndrome (D-IBS). ...more
Tioga's lead product is asimadoline, a proprietary,
peripherally restricted small molecule kappa opioid agonist,
originally discovered by Merck KGaA of Darmstadt, Germany.
Asimadoline is currently in Phase 3 clinical development for the treatment of irritable bowel syndrome (IBS) ...more
Asimadoline is currently in Phase 3 clinical development for the treatment of irritable bowel syndrome (IBS) ...more
IBS is a common condition that is found in high prevalence throughout the world. Affected patients
experience recurrent episodes of abdominal pain or discomfort associated with a change in bowel pattern ...more